Protein S deficiency present in a pregnant woman with dyspnea, abdominal pains, restlessness, agitation and hypofibrinogenemia

Author(s)
Umazume, Takeshi; Morikawa, Mamoru; Yamada, Takahiro; Akaishi, Rina; Koyama, Takahiro; Minakami, Hisanori

Citation
Clinical case reports, 3(4): 213-216

Issue Date
2015-04

Doc URL
http://hdl.handle.net/2115/60659

Rights(URL)
http://creativecommons.org/licenses/by-nc-nd/3.0/

Type
article
Protein S deficiency present in a pregnant woman with dyspnea, abdominal pains, restlessness, agitation and hypofibrinogenemia

Takeshi Umazume, Mamoru Morikawa, Takahiro Yamada, Rina Akaishi, Takahiro Koyama & Hisanori Minakami

Department of Obstetrics, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan

Introduction

Blood fibrinogen level increases during pregnancy from a nonpregnant level of 2.5 ± 0.7 g/L to 4.5 ± 0.9 g/L at gestational week (GW) 30–33 [1], partly explaining the hypercoagulable state of pregnancy. As fibrinogen is a soluble precursor of fibrin and D-dimer is a specific degradation product of cross-linked fibrin monomers, a decrease in fibrinogen level can occur in clinical situations with acute and aggressive increases in the D-dimer level [2]. With increasing pulmonary occlusion rate, fibrinogen level decreases and D-dimer level increases in pulmonary thromboembolism (PTE) [2]. However, hypofibrinogenemia defined as <0.5 g/L is seldom seen in patients with PTE [2, 3].

Although amniotic fluid embolism (AFE) is a leading cause of maternal mortality in developed countries, occurring in approximately 1 in 20,000–30,000 pregnancies, its pathogenesis remains unclear [4, 5]. Some blood parameters, such as elevated levels of STN and IL-8, were suggested to be associated with the occurrence of AFE [6, 7]. However, as no reliable blood parameters are available for diagnosis, AFE is almost a diagnosis of exclusion and is clinically based on one or more of four key signs/symptoms: cardiovascular collapse, respiratory distress, coagulopathy, and/or coma/seizures [5].

Here, we report a pregnant woman in whom a marked D-dimer increase concomitant with a very acute decrease in fibrinogen to an undetectable level occurred. This presentation was conducted after receiving approval by the patient and the Ethics Committee of Hokkaido University Hospital.

Case Description

A 35-year-old Japanese woman with monochorionic diamniotic twin pregnancy and pre-pregnancy body mass index of 19.6 kg/m² presented with stabbing pain in the lower abdomen at gestational week (GW) 30–37. Her medical history was unremarkable except for asthma with...
prior birth of a healthy girl 5 years ago. She was unstable and apparently ill with difficulty in breathing, agitation, and restlessness despite body temperature of 36.8°C, blood pressure of 119/69 mmHg, pulse rate of 105 bpm, no proteinuria on dipstick test, and unremarkable test results on SPO₂ monitoring (99%), ultrasound/Doppler study in the abdomen and lower extremities, echocardiography. Although these studies suggested increased uterine activity, but not placental abruption, cardiac stroke, deep vein thrombosis (DVT), pulmonary thromboembolism (PTE), or AFE, marked elevation of D-dimer (370 and 376 µg/mL again on reexamination) concomitant with reduced fibrinogen level (1.7 and 1.6 g/L again on reexamination) (Fig. 1) in the presence of normal liver function (AST/ALT, 20 and 12 IU/L, respectively) prompted us to initiate intravenous continuous administration of unfractionated heparin at a rate of 833 units/h and intravenous ritodrine hydrochloride for suppression of uterine activity; subsequent tests indicated undetectable fibrinogen level (<0.5 g/L) 3 h later in this patient. She received 3.0 g of fibrinogen, resulting in an unexpected rise in fibrinogen level to 2.7 g/L. She became stable with regard to subjective symptoms, such as dyspnea, abdominal pain, restlessness, and agitation, within 12 h, exhibited no bleeding diathesis, and showed an uneventful course thereafter. However, she experienced premature rupture of the fetal membranes 6 days later at GW 31^{4/7} and underwent cesarean section, giving birth to two healthy boys weighing 1396 and 1334 g (Apgar scores of 8 and 9 at 1 and 5 min, respectively, for both infants). Computed tomography (CT) was performed after delivery to avoid fetal exposure to radiation, although she was entirely asymptomatic. Right PTE detected on CT on postpartum day (PPD) 1 had disappeared on repeat CT on PPD 10 (Fig. 2).

The patient was given warfarin and left hospital on PPD 17. The patient was screened for thrombophilia (Table 1). Protein S activity was consistently low even after delivery, and congenital protein S deficiency was diagnosed in this patient.

**Discussion**

We speculated that an extraordinary acute and massive thrombus formation associated with protein S deficiency occurred in the deep veins of this patient in a short time based on marked elevation of D-dimer to 376 µg/mL concomitant with depletion of fibrinogen to an undetectable level (<0.5 g/L).

Although the D-dimer level is significantly higher in pregnant than nonpregnant women [8, 9] and in women with twin than singleton pregnancies [10], its rarely exceeds 10 µg/mL at this stage (GW 31) of pregnancy [9, 10], at which time fibrinogen level is around 4.5 g/L in otherwise healthy pregnant women [1]. According to
Kucher et al. [2], such profound hypofibrinogenemia <0.5 g/L may not occur in PTE cases unless more than 80% pulmonary occlusion occurs. The D-dimer level did not exceed 30 μg/mL even in pregnant patients with DVT/PTE [9]. DVT, PTE, or abnormalities in cardiac function were not detected on ultrasound or Doppler studies in our patient, while she was unstable and showed dyspnea despite sufficient oxygenation as determined by SPO2 monitoring.

Placental abruption is a common complication (occurring in approximately 1 in 100 women [11]) in which abdominal pain and fibrinogen depletion are likely to occur [12] and the fetal condition monitored by fetal heart rate pattern progressively worsens. However, fetal well-being was maintained throughout the clinical course in this patient.

As pathogenesis of AFE remains unclear, AFE is ill defined and diagnosed based on clinical symptoms [4, 5]. Patients with AFE exhibit one or more of the following four clinical symptoms: cardiovascular collapse, respiratory distress, coagulopathy, and/or coma/seizures [4, 13]. However, premonitory neurological symptoms, including restlessness, agitation, numbness, and tingling, are seen in 30–65% of AFE cases [13], as in the present case. With regard to coagulopathy and the diagnosis of AFE, fibrinogen level was <2.0 g/L in 32 (94%), <1.0 g/dL in 17 (50%), and undetectable in 8 (24%) of 34 AFE patients with laboratory assessment of coagulopathy [14]. In addition, coagulopathy alone was described as the sole clinical sign/symptom of AFE in at least five AFE cases [15–19]. Our patient had laboratory coagulopathy and would have developed bleeding diathesis unless fibrinogen was replaced in a timely manner because there is a strong association between fibrinogen activity level and clinical severity of bleeding [20].

The fibrinogen level was undetectable (<0.5 g/L) in this patient before replacement of fibrinogen. As the estimated circulating blood volume was 5000 mL in this patient, the exogenous 3.0 g of fibrinogen would have contributed to a net increase in fibrinogen level by 0.50 g/L. However, the patient showed a fibrinogen level of ≥2.7 g/L after a single replacement of fibrinogen. This suggested the occurrence of hyperproduction of fibrinogen to respond to acute and massive consumption of fibrinogen in this critically ill patient.

Transient shortness of breath, palpitations, and laboratory evidence for coagulopathy were documented in a patient with possible “mild” AFE [21], as seen in our patient. Although our patient was finally diagnosed as having PTE with CT on PPD 1 in the absence of decreased oxygenation in the blood, the clinical course was very unusual for PTE. The pathogenesis leading to the present symptoms and findings may have some features similar to AFE. However, a route of amniotic fluid entrance to the general circulation was unclear if AFE was assumed to have occurred in this patient.

**Disclosure**

All authors declare that they have no financial relationships with biotechnology manufacturers, pharmaceutical companies, or other commercial entities with an interest in the subject matter or materials discussed in this manuscript.

**Acknowledgements**

This study was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports, and Culture of Japan (No. 2646246804).

**Conflict of Interest**

None declared.

**References**